RT Journal Article
SR Electronic
T1 SARS-CoV-2 infected cells trigger an acute antiviral response mediated by Plasmacytoid dendritic cells in mild but not severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.01.21262969
DO 10.1101/2021.09.01.21262969
A1 Venet, Manon
A1 Ribeiro, Margarida Sa
A1 Décembre, Elodie
A1 Bellomo, Alicia
A1 Joshi, Garima
A1 Villard, Marine
A1 Cluet, David
A1 Perret, Magali
A1 Pescamona, Rémi
A1 Paidassi, Helena
A1 Walzer, Thierry
A1 Allatif, Omran
A1 Belot, Alexandre
A1 Assant, Sophie
A1 Ricci, Emiliano
A1 Dreux, Marlène
YR 2021
UL http://medrxiv.org/content/early/2021/09/08/2021.09.01.21262969.abstract
AB Type I and III interferons (IFN-I/λ) are key antiviral mediators against SARS-CoV-2 infection. Here, we demonstrate that the plasmacytoid dendritic cells (pDCs) are predominant IFN-I/λ source by sensing SARS-CoV-2-infected cells. We show that sensing of viral RNA by pDCs requires sustained cell adhesion with infected cells. In turn, the pDCs restrict viral spread by a local IFN-I/λ response directed toward SARS-CoV-2-infected cells. This specialized function enables pDCs to efficiently turn-off viral replication, likely by a concentrated flux of antiviral effectors at the contact site with infected cells. Therefore, we propose that pDC activation is essential to locally control SARS-CoV-2-infection. By exploring the pDC response in patients, we further demonstrate that pDC responsiveness correlates with the severity of the disease and in particular that it is impaired in severe COVID-19 patients. Thus, the ability of pDCs to respond to SARS-CoV-2-infected cells could be a key to understand severe cases of COVID-19.HighlightspDCs are immune cells against SARS-CoV-2-infected cellspDC-mediated IFN-I/λ response against SARS-CoV-2 infected cells control COVID- 19 progressionpDC response by SARS-CoV-2 is restricted to IRF7-prioritized signaling leading to antiviral controlpDC antiviral response directed toward contacting SARS-CoV-2-infected cellsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementFunding are include in the acknowledgment sectionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethics committee from EFS and HCLAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript will be available